Resistance to targeted therapies in breast cancer

We present an in-depth description of resistance to targeted therapies in breast cancer. Targeted therapies discussed here include those used to treat ER+ or Her2+ breast cancers (i.e., Tamoxifen or trastuzumab) or those targeting signaling pathways aberrantly activated in triple negative breast can...

Full description

Saved in:
Bibliographic Details
Other Authors: Prosperi, Jenifer R., (Editor)
Format: eBook
Language: English
Published: Cham, Switzerland : Springer, [2017]
Series: Resistance to targeted anti-cancer therapeutics ; v. 16.
Subjects:
Breast > Cancer > Chemotherapy.
Drug resistance in cancer cells.
elektronické knihy
electronic books
ISBN: 9783319701424
9783319701417
Physical Description: 1 online resource

Cover

Table of contents

LEADER 03042cam a2200433Ii 4500
001 97674
003 CZ-ZlUTB
005 20201031110017.0
006 m o d
007 cr cnu|||unuuu
008 171212t20172017sz ob 001 0 eng d
040 |a N$T  |b eng  |e rda  |e pn  |c N$T  |d N$T  |d GW5XE  |d EBLCP  |d OCLCF  |d UAB  |d VT2  |d AZU  |d UPM  |d MERER  |d OCLCQ  |d SNK  |d OCLCQ  |d U3W  |d YDX  |d IOG  |d KSU  |d AU@  |d ESU  |d WYU  |d OCLCQ  |d LVT  |d COD  |d UKMGB  |d CAUOI  |d UKAHL  |d OCLCQ 
020 |a 9783319701424  |q (electronic bk.) 
020 |z 9783319701417 
024 7 |a 10.1007/978-3-319-70142-4  |2 doi 
035 |a (OCoLC)1015239639  |z (OCoLC)1015862170  |z (OCoLC)1021201686  |z (OCoLC)1026949350  |z (OCoLC)1032269241  |z (OCoLC)1048126354  |z (OCoLC)1058492774  |z (OCoLC)1066475847  |z (OCoLC)1097138998 
245 0 0 |a Resistance to targeted therapies in breast cancer /  |c Jenifer R. Prosperi, editor. 
264 1 |a Cham, Switzerland :  |b Springer,  |c [2017] 
264 4 |c ©2017 
300 |a 1 online resource 
336 |a text  |b txt  |2 rdacontent 
337 |a počítač  |b c  |2 rdamedia 
338 |a online zdroj  |b cr  |2 rdacarrier 
490 1 |a Resistance to targeted anti-cancer therapeutics,  |x 2196-551X ;  |v volume 16 
504 |a Includes bibliographical references and index. 
505 0 |a Invasive Breast Cancer Therapy 2017: How Well Are We Hitting The Target? -- Resistance to HER2-targeted therapy -- Endocrine Resistance and Breast Cancer Stem Cells? The Inflammatory Connection That Could Lead to New and Improved Therapy Outcomes -- EGFR Resistance -- Targeting FGFR for the treatment of breast cancer -- Targeted Therapies in Breast Cancer -- Future paradigm of breast cancer resistance and treatment. 
506 |a Plný text je dostupný pouze z IP adres počítačů Univerzity Tomáše Bati ve Zlíně nebo vzdáleným přístupem pro zaměstnance a studenty 
520 |a We present an in-depth description of resistance to targeted therapies in breast cancer. Targeted therapies discussed here include those used to treat ER+ or Her2+ breast cancers (i.e., Tamoxifen or trastuzumab) or those targeting signaling pathways aberrantly activated in triple negative breast cancer (i.e., EGFR and Wnt signaling). We have also provided an overview of standard of care as an introduction into the importance of targeted therapy. It is our hope that this volume gives an insight into the landscape of breast cancer treatment, the challenges of targeted therapy, and a glimpse into the future of breast cancer therapy. #xE000. 
590 |a SpringerLink  |b Springer Complete eBooks 
650 0 |a Breast  |x Cancer  |x Chemotherapy. 
650 0 |a Drug resistance in cancer cells. 
655 7 |a elektronické knihy  |7 fd186907  |2 czenas 
655 9 |a electronic books  |2 eczenas 
700 1 |a Prosperi, Jenifer R.,  |e editor. 
776 0 8 |i Printed edition:  |z 9783319701417 
830 0 |a Resistance to targeted anti-cancer therapeutics ;  |v v. 16. 
856 4 0 |u https://proxy.k.utb.cz/login?url=https://link.springer.com/10.1007/978-3-319-70142-4  |y Plný text 
992 |c NTK-SpringerBLS 
999 |c 97674  |d 97674 

Similar Items